Cargando…

The Use of Rifaximin in Patients With Cirrhosis

Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caraceni, Paolo, Vargas, Victor, Solà, Elsa, Alessandria, Carlo, de Wit, Koos, Trebicka, Jonel, Angeli, Paolo, Mookerjee, Rajeshwar P., Durand, François, Pose, Elisa, Krag, Aleksander, Bajaj, Jasmohan S., Beuers, Ulrich, Ginès, Pere
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518409/ https://www.ncbi.nlm.nih.gov/pubmed/33421158 http://dx.doi.org/10.1002/hep.31708

Ejemplares similares

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
por: Pose, Elisa, et al.
Publicado: (2021)

Albumin in decompensated cirrhosis: new concepts and perspectives
por: Bernardi, Mauro, et al.
Publicado: (2020)

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial
por: Madsen, Bjørn Stæhr, et al.
Publicado: (2018)

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure
por: Blaya, Delia, et al.
Publicado: (2021)

Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis
por: Trebicka, Jonel, et al.
Publicado: (2019)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Gut Microbiota as Biosensors in Patients With Cirrhosis
por: Bajaj, Jasmohan S.
Publicado: (2019)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Rifaximin as a rare cause of rhabdomyolysis in cirrhosis
por: Rezigh, Alec B., et al.
Publicado: (2018)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Whoop there it is: decoding sleep, cirrhosis, and HE
por: Badal, Bryan D., et al.
Publicado: (2023)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension
por: Trebicka, Jonel, et al.
Publicado: (2013)

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues
por: Montagnese, Sara, et al.
Publicado: (2019)

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
por: Israelsen, Mads, et al.
Publicado: (2023)

Letter to the Editor: Subjective and objective burden on providers from a multicenter app-based study of patients with cirrhosis and caregivers
por: Gananandan, Kohilan, et al.
Publicado: (2023)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis
por: Torp, Nikolaj, et al.
Publicado: (2021)

Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis
por: Tatsumi, Ryoji, et al.
Publicado: (2020)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Assessment of bilirubin levels in patients with cirrhosis via forehead, sclera and lower eyelid smartphone images
por: Nixon-Hill, Miranda, et al.
Publicado: (2023)

Management of Ascites in Patients with Cirrhosis: An Update
por: Zaccherini, Giacomo, et al.
Publicado: (2021)

Corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]
por: Torp, Nikolaj, et al.
Publicado: (2021)

Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis
por: Graupera, Isabel, et al.
Publicado: (2016)

High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal
por: Kjærgaard, Maria, et al.
Publicado: (2017)

Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition
por: Kang, Dae J, et al.
Publicado: (2016)

Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients’ Experience on Rifaximin-α (PROSPER): an observational study among 550 patients
por: Krag, Aleksander, et al.
Publicado: (2018)

Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites
por: Lutz, Philipp, et al.
Publicado: (2014)

Cirrhosis, bile acids and gut microbiota: Unraveling a complex relationship
por: Ridlon, Jason M, et al.
Publicado: (2013)

Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes
por: Graupera, Isabel, et al.
Publicado: (2017)

Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents
por: Zaccherini, Giacomo, et al.
Publicado: (2021)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dt1p7paih5ssc1fiaennmc8gm6